A Phase II Multi-Center Trial
Montillo M, Rossi D, Motta M, et al.
Key Points:
Phase II trial to assess Pentostatin, Cyclophosphamide and Ofatumumab x 6 cycles in therapy requiring elderly CLL patients
Primary endpoint: overall response rate (ORR) including detection of minimal residual disease (MRD)
Secondary endpoints: progression-free survival (PFS), overall survival (OS) and safety
ORR:93.7%, CR: 41%
94% patients received 6 cycles, 90% of these patients received full-dose treatment
Primary reason for discontinuing treatment/dose reduction: myelosuppression
Grade ≥3 AEs was neutropenia (62%)
No deaths occurred during treatment.
Implications:
- Efficacy of ofatumumab-based chemoimmunotherapy (CIT) compares favorably to historical rituximab-based CIT with more manageable side effect profile in older population.
Additional Comments:
- Further data in higher number of enrolled patients and including MRD detection to be presented at ASH.
View the original abstract on the ASH website.
